Dermata Therapeutics Announces Participation at the H . C . Wainwright 26th Annual Global Investment Conference September 9 – 11 , 2024. Let’s break down the company and the conference. Dermata

Wainwright Global Healthcare Conference. Dermata’s presentation will focus on the Company’s pipeline of innovative therapies for skin diseases, including its lead product candidate, Derma-C, which is currently in Phase 3 clinical trials for the treatment of moderate to severe acne vulgaris. The presentation will highlight the Company’s commitment to developing novel therapies for skin diseases, emphasizing its expertise in dermatology and its focus on addressing unmet medical needs. Dermata’s pipeline of innovative therapies includes a range of products targeting different aspects of skin health, from topical treatments to systemic therapies.

Eastern Time. The conference will be hosted by H.C. Wainwright & Co., a leading investment bank and financial services firm. The event will feature a diverse range of speakers, including CEOs, CFOs, and industry experts.

* **Corporate Finance:** H.C.